Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2026)

Cogent Biosciences' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $58.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 17.57% year-over-year to $58.0 million; the TTM figure through Mar 2026 stood at $58.0 million (up 17.57% YoY), while the FY2025 annual figure was $64.0 million, up 14.8% from the prior year.
• Total Current Liabilities was $58.0 million for Q1 2026 at Cogent Biosciences, down from $64.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $64.0 million in Q4 2025 to a low of $17.9 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $40.8 million across 5 years, with a median of $38.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 116.93% in 2022, then fell 6.87% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $26.8 million in 2022, then soared by 42.16% to $38.2 million in 2023, then surged by 45.96% to $55.7 million in 2024, then grew by 14.8% to $64.0 million in 2025, then dropped by 9.34% to $58.0 million in 2026.
• The last three Total Current Liabilities figures came in at $58.0 million (Q1 2026), $64.0 million (Q4 2025), and $62.2 million (Q3 2025), per Business Quant data.